Tes­sa en­joyed big back­ers, great sci­ence and world-class am­bi­tion. So what did we learn from its col­lapse?

Tes­sa Ther­a­peu­tics’ web­site has gone dark. Any­one Googling up ref­er­ences to a re­view of the pipeline, the peo­ple, its hun­dreds of mil­lions raised for can­cer R&D, its still rather new CEO, are led to a sim­ple no­tice:

“Web­site is un­der main­te­nance.”

But not re­al­ly.

As Kyle LaHu­cik ably re­port­ed a few days ago, Sin­ga­pore-based Tes­sa has fold­ed its tent. And the prin­ci­pals, as usu­al in a shut­down, don’t have a lot to say about it.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.